Xiaozhong Qian
- Oncology top 5%
- Lung Cancer Research Studies 6
- HER2/EGFR in Cancer Research 4
- Cancer Immunotherapy and Biomarkers 4
- Peptidase Inhibition and Analysis 3
- Molecular Biology top 5%
- Histone Deacetylase Inhibitors Research 9
- Protein Degradation and Inhibitors 8
- Epigenetics and DNA Methylation 3
- Physiology top 10%
-
- Monoclonal and Polyclonal Antibodies Research 3
- Co-authors
- David D. GintyMichael JeffersHenri S. LichensteinMaxwell SehestedYuan ZhangLaura S. CollinsWilliam J. LaRochelleJames W.A. Ritchie
- Partner nations
- United StatesJapanUnited Kingdom
In The Last Decade
Xiaozhong Qian
36 papers receiving 2.0k citations
Hit Papers
Peers
Comparison fields: 5 of 100
- Oncology 627
- Molecular Biology 1.3k
- Cellular and Molecular Neuroscience 260
- Physiology 339
- Immunology 211
Countries citing papers authored by Xiaozhong Qian
This map shows the geographic impact of Xiaozhong Qian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaozhong Qian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaozhong Qian more than expected).
Fields of papers citing papers by Xiaozhong Qian
This network shows the impact of papers produced by Xiaozhong Qian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaozhong Qian. The network helps show where Xiaozhong Qian may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Xiaozhong Qian, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2025 | 0 | |
| 3 | 2023 | 23 | |
| 4 | 2023 | 9 | |
| 5 | 2022 | 7 | |
| 6 | 2021 | 76 | |
| 7 | 2021 | 23 | |
| 8 | 2021 | 18 | |
| 9 | 2020 | 7 | |
| 10 | 2020 | 166 | |
| 11 | 2018 | 36 | |
| 12 | 2017 | 1 | |
| 13 | 2014 | 10 | |
| 14 | 2008 | 35 | |
| 15 | 2008 | 47 | |
| 16 | 2007 | 79 | |
| 17 | 2006 | 117 | |
| 18 | Activity of the HDAC inhibitor, PXD101, used as monotherapy and combination therapy in preclinical NSCLC studies | 2006 | 1 |
| 19 | 1998 | 195 | |
| 20 | 1998 | 316 |
About Xiaozhong Qian
Xiaozhong Qian is a scholar working on Oncology, Gastroenterology and Hematology, having authored 37 papers that have together received 2.0k indexed citations. Recurring topics across this work include Histone Deacetylase Inhibitors Research (9 papers), Protein Degradation and Inhibitors (8 papers), Lung Cancer Research Studies (6 papers), HER2/EGFR in Cancer Research (4 papers), Cancer Immunotherapy and Biomarkers (4 papers), Peptidase Inhibition and Analysis (3 papers), Monoclonal and Polyclonal Antibodies Research (3 papers) and Epigenetics and DNA Methylation (3 papers). The work is most often cited by research in Oncology (627 citations), Molecular Biology (1.3k citations) and Cellular and Molecular Neuroscience (260 citations). Xiaozhong Qian has collaborated with scholars based in United States, Japan and United Kingdom. Frequent co-authors include David D. Ginty, Michael Jeffers, Henri S. Lichenstein, Maxwell Sehested, Yuan Zhang, Laura S. Collins, William J. LaRochelle, James W.A. Ritchie, Ferenc Boldog and Sampath Kumar. Their work appears in journals such as Neuron, Journal of Clinical Oncology and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.